Advantages of extended-release metformin in patients with type 2 diabetes mellitus

Postgraduate Medicine

Volumn 123, Issue 1, 2011, Pages 15-23

  Jabbour, Serge ^a   Ziring, Barry ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Adherence; Efficacy; Extended release metformin; Tolerability; Type 2 diabetes mellitus

Indexed keywords

METFORMIN; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS SAXAGLIPTIN; METFORMIN PLUS SITAGLIPTIN; PLACEBO; SULFONYLUREA; ANTIDIABETIC AGENT;

ABDOMINAL PAIN; ARTICLE; COMORBIDITY; CONTROLLED DRUG RELEASE; DECREASED APPETITE; DIABETIC PATIENT; DIARRHEA; DRUG ABSORPTION; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG TOLERABILITY; DYSPEPSIA; EVENING DOSAGE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEARTBURN; HUMAN; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; VOMITING; DELAYED RELEASE FORMULATION; REVIEW;

DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; MEDICATION ADHERENCE; METFORMIN;

EID: 79952790301     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2011.01.2241     Document Type: Article

References (33)

1. Nathan DM, Buse JB, Davidson MB, et al; American Diabetes Association; European Association for Study of Diabetes. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009;32(1):193-203.
2. Rodbard HW, Jellinger PS, Davidson JA, et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology Consensus Panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract. 2009;15(6):540-559.
3. Garber AJ, Duncan TG, Goodman AM, Mills DJ, Rohlf JL. Efficacy of metformin in type II diabetes: results of a double-blind, placebocontrolled, dose-response trial. Am J Med. 1997;103(6):491-497.
4. Levy J, Cobas RA, Gomes MB. Assessment of efficacy and tolerability of once-daily extended release metformin in patients with type 2 diabetes mellitus. Diabetol Metab Syndr. 2010;2:16.
5. Donnelly LA, Morris AD, Pearson ER. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. Diabetes Obes Metab. 2009;11(4): 338-342.
6. Schwartz S, Fonseca V, Berner B, Cramer M, Chiang YK, Lewin A. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care. 2006;29(4): 759-764.
7. Kirpichnikov D, McFarlane SI, Sowers JR. Metformin: an update. Ann Intern Med. 2002;137(1):25-33.
8. Kim YD, Park KG, Lee YS, et al. Metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes. 2008;57(2): 306-314.
9. Timmins P, Donahue S, Meeker J, Marathe P. Steady-state pharmacokinetics of a novel extended-release metformin formulation. Clin Pharmacokinet. 2005;44(7):721-729.
10. Davidson J, Howlett H. New prolonged-release metformin improves gastrointestinal tolerability. Brit J Diabetes Vasc Dis. 2004;4(4): 273-277.
11. Glucophage XR [package insert]. Princeton, NJ: Bristol-Myers Squibb; 2009.
12. Glumetza [package insert]. Menlo Park, CA: Depomed, Inc; 2008.
13. Fortamet [package insert]. Atlanta, GA: Shionogi Pharma, Inc; 2010.
14. Kombiglyze XR [package insert]. Princeton, NJ: Bristol-Myers Squibb Company, and Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2010.
15. Actoplus Met [package insert]. Deerfield, IL: Takeda Pharmaceuticals America, Inc; March 2009.
16. Fujioka K, Brazg RL, Raz I, et al. Efficacy, dose-response relationship and safety of once-daily extended-release metformin (Glucophage XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double-blind, placebo-controlled studies. Diabetes Obes Metab. 2005;7(1):28-39.
17. Fujioka K, Pans M, Joyal S. Glycemic control in patients with type 2 diabetes mellitus switched from twice-daily immediate-release metformin to a once-daily extended-release formulation. Clin Ther.2003;25(2):515-529.
18. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352(9131): 854-865.
19. Hsieh CH, He CT, Lee CH, Wu LY, Hung YJ. Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus. Metabolism. 2007;56(8):1087-1092.
20. Sweeny M, DeFronzo R, Scinta W. Tolerability of metformin gastroretentive formulation (M-GR) in patients previously intolerant of metformin [ADA abstract 729-P]. Diabetes. 2010;59(suppl 1):A199.
21. Blonde L, Dailey GE, Jabbour SA, Reasner CA, Mills DJ. Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort study. Curr Med Res Opin. 2004;20(4):565-572.
22. Bramley TJ, Gerbino PP, Nightengale BS, Frech-Tamas F. Relationship of blood pressure control to adherence with antihypertensive monotherapy in 13 managed care organizations. J Manag Care Pharm.2006;12(3):239-245.
23. Elliott WJ. What factors contribute to the inadequate control of elevated blood pressure? J Clin Hypertens (Greenwich). 2008;10(1 suppl 1):20-26.
24. Penning-van Beest FJ, van der Bij S, Erkens JA, Kessabi S, Groot M, Herings RM. Effect of non-persistent use of oral glucose-lowering drugs on HbA1c goal attainment. Curr Med Res Opin. 2008;24(9):2523-2529.
25. Balkrishnan R, Rajagopalan R, Camacho FT, Huston SA, Murray FT, Anderson RT. Predictors of medication adherence and associated health care costs in an older population with type 2 diabetes mellitus: a longitudinal cohort study. Clin Ther. 2003;25(11):2958-2971.
26. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation. 2009;119(23):3028-3035.
27. Düsing R. Adverse events, compliance, and changes in therapy. Curr Hyperten Rep. 2001;3(6):488-492.
28. Feher MD, Al-Mrayat M, Brake J, Leong KS. Tolerability of prolongedrelease metformin (Glucophage SR) in individuals intolerant to standard metformin results from four UK centres. Brit J Diabetes Vasc Dis.2007;7:225-228.
29. Shaya FT, Du D, Gbarayor CM, Frech-Tamas F, Lau H, Weir MR. Predictors of compliance with antihypertensive therapy in a high-risk Medicaid population. J Natl Med Assoc. 2009;101(1):34-39.
30. Balu S, Simko RJ, Quimbo RM, Cziraky MJ. Impact of fixed-dose and multi-pill combination dyslipidemia therapies on medication adherence and the economic burden of sub-optimal adherence. Curr Med Res Opin.2009;25(11):2765-2775.
31. Hess G, Hill J, Lau H, Dastani H, Chaudhari P. Medication utilization patterns and hypertension-related expenditures among patients who were switched from fixed-dose to free-combination antihypertensive therapy. P T. 2008;33(11):652-666.
32. van Santen, Barends DM, Frijlink HW. Breaking of scored tablets: a review. Eur J Pharm Biopharm. 2002;53(2):139-145.
33. Rodenhuis N, De Smet PA, Barends DM. The rationale of scored tablets as dosage form. Eur J Pharm Sci. 2004;21(2-3):305-308.